

1 **A Multi-Centre, Tolerability Study of a Cannabidiol-enriched Cannabis Herbal Extract for**  
2 **Chronic Headaches in Adolescents: the CAN-CHA Protocol**

3  
4 Manik Chhabra<sup>1</sup>, Evan C. Lewis<sup>2</sup>, Robert Balshaw<sup>3</sup>, Breanne Stewart<sup>4,5</sup>, Zina Zaslowski<sup>6</sup>, Trinity  
5 Lowthian<sup>7</sup>, Zahra Alidina<sup>7</sup>, Melila Chesick-Gordis<sup>7</sup>, Wenli Xie<sup>5</sup>, Britt I. Drögemöller<sup>8</sup>, Galen  
6 E.B. Wright<sup>1</sup>, Kathryn A Birnie<sup>9</sup>, Katelynn E Boerner<sup>10</sup>, Vivian W. L. Tsang<sup>5, 10</sup>, Samantha Lee  
7 Irwin<sup>11</sup>, Daniela Pohl<sup>12</sup>, Alexander G Weil<sup>13</sup>, Erick Sell<sup>12</sup>, Erika Penz<sup>14</sup>, Amy Robson-  
8 MacKay<sup>15</sup>, Sophia Mbabaali<sup>3</sup>, Stephanie Blackman<sup>16,17</sup>, Shanlea Gordon<sup>10</sup>, Jane Alcorn<sup>18,19</sup>,  
9 Richard J. Huntsman<sup>18,20</sup>, Tim F Oberlander<sup>10</sup>, G Allen Finley<sup>16,17</sup>, Lauren E Kelly<sup>1,6</sup>

- 10  
11  
12 1. Department of Pharmacology & Therapeutics, Max Rady College of Medicine,  
13 University of Manitoba, Winnipeg, MB, Canada  
14 2. Neurology Centre of Toronto, Toronto ON, Canada  
15 3. George and Fay Yee Centre for Healthcare Innovation, University of Manitoba,  
16 Winnipeg, Manitoba, Canada  
17 4. Quality Management in Clinical Research (QMCR), University of Alberta,  
18 Edmonton, AB, Canada  
19 5. Maternal Infant Child and Youth Research Network (MICYRN), Vancouver, British  
20 Columbia, Canada  
21 6. Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB,  
22 Canada  
23 7. Youth research partners  
24 8. Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences,  
25 University of Manitoba, Winnipeg, Manitoba, Canada  
26 9. Department of Anesthesiology, Perioperative and Pain Medicine, University of  
27 Calgary, AB, Canada  
28 10. Department of Pediatrics, BC Children's Hospital Research Institute, University of  
29 British Columbia, Vancouver, BC, Canada  
30 11. University of California, San Francisco (UCSF) Child and Adolescent Headache  
31 Program. Department of Neurology, UCSF Weill Institute for Neurosciences, UCSF  
32 Benioff Children's Hospitals.  
33 12. Division of Neurology, Children's Hospital of Eastern Ontario, University of Ottawa  
34 ON, Canada.  
35 13. Pediatric Neurosurgery, Department of Surgery, Sainte Justine Hospital, University of  
36 Montreal, Montreal, Quebec, Canada  
37 14. Department of Medicine, College of Medicine, University of Saskatchewan,  
38 Saskatchewan, Canada  
39 15. Department of Psychiatry, College of Medicine, University of Saskatchewan,  
40 Saskatoon, SK, Canada  
41 16. Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie  
42 University, Halifax, Nova Scotia, Canada  
43 17. Center for Pediatric Pain Research, IWK Health, Halifax, Nova Scotia, Canada  
44 18. Cannabinoid Research Initiative of Saskatchewan, University of Saskatchewan,  
45 Saskatoon, SK, Canada

- 46 19. College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK,  
47 Canada  
48 20. Department of Pediatrics, Royal University Hospital, University of Saskatchewan,  
49 Saskatoon, SK, Canada  
50

51

52 **Word count** 5743

53

54 **Short title** Cannabis for Chronic Headaches in Adolescents

55

56 **Corresponding Author**

57 Lauren E Kelly PhD, MSc, BMedSci, CCRP

58 Assistant Professor, Dept. of Pharmacology and Therapeutics, University of Manitoba

59 Scientific Director, Canadian Childhood Cannabinoid Clinical Trials ([www.C4Trials.org](http://www.C4Trials.org))

60 417 – 753 McDermot Ave, Winnipeg Manitoba R3E0T6

61 Email: [lauren.elyse.kelly@gmail.com](mailto:lauren.elyse.kelly@gmail.com)

62 Phone: 204 272 3190

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77 **Abstract**

78 **Introduction**

79 Cannabis products have been used in the management of headaches in adults and may play a role  
80 in pediatric chronic pain. Canadian pediatricians report increasing use of cannabis for the  
81 management of chronic headaches, despite no well-controlled studies to inform its dosing,  
82 safety, and effectiveness. The aim of our clinical trial is to determine the dosing and safety of a  
83 Cannabidiol (CBD)-enriched Cannabis Herbal Extract (CHE) for the treatment of chronic  
84 headaches in adolescents.

85 **Methods and analysis**

86 Youth, parents and an expert steering committee co-designed this tolerability study. Twenty  
87 adolescents (aged 14 to 17 years), with a chronic migraine diagnosis for more than 6 months that  
88 has not responded to other therapies, will be enrolled into an open label, dose escalation study  
89 across three Canadian sites. Study participants will receive escalating doses of a CBD-enriched  
90 CHE (MPL-001 with a THC:CBD of 1:25), starting at 0.2-0.4 mg/kg of CBD per day escalating  
91 monthly up to 0.8-1.0 mg/kg of CBD per day. The primary objective of this study is to determine  
92 the safety and tolerability of CBD-enriched CHE in adolescents with chronic migraine.  
93 Secondary objectives of this study will inform the development of subsequent randomized  
94 controlled trials and include investigating the relationship between the dose escalation and  
95 change in the frequency of headache, impact and intensity of pain, changes in sleep, mood,  
96 function, and quality of life. Exploratory outcomes include investigating steady-state trough  
97 plasma levels of bioactive cannabinoids and investigating how pharmacogenetic profiles affect  
98 cannabinoid metabolism among adolescents receiving CBD-enriched CHE.

99 **Discussion**

100 This protocol was co-designed with youth and describes a tolerability clinical trial of CBD-  
101 enriched CHE in adolescents with chronic headaches that have not responded to conventional  
102 therapies. This study is the first clinical trial on cannabis products in adolescents with chronic  
103 headaches and will inform the development of future comparative effectiveness clinical trials.

104

105 **Trial registration:** CAN-CHA trial is registered with ClinicalTrials.gov with a number of  
106 register NCT05337033.

107 **Keywords:** Cannabidiol; migraine, chronic headache; safety; adolescents; medical cannabis

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

## 124 **Introduction**

125 Globally, chronic headaches are one of the major causes of disability among adolescents. The  
126 World Health Organization classifies it under the top ten disabling health conditions,[1, 2] with a  
127 prevalence of 7.8% in adolescents 14 years of age or older [3-5]. In the US alone, the total  
128 annual cost incurred by pediatric headache is estimated around \$1.1 billion [6]. Adolescents with  
129 chronic headaches often experience reduced quality of life, sleep disruption, anxiety, fatigue,  
130 limb pain, dizziness, overuse of medications and academic challenges [7]. Despite advancements  
131 in the therapeutic management of chronic pain, treatment of chronic headache disorders in  
132 adolescents remains challenging. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), triptans,  
133 gabapentin, neuromodulation devices and ergotamine are used for the acute treatment of  
134 migraine [8, 9]. Preventive migraine therapies are limited in availability, efficacy, and  
135 authorization for use in the adolescent population. Topiramate is the only FDA approved  
136 preventive treatment for migraine in adolescents [1, 10, 11]. In other areas of medicine,  
137 cannabinoids have shown therapeutic potential in adolescents where conventional medications  
138 fail, including treatment resistant epilepsy, and chemotherapy-induced nausea and vomiting [12].  
139 In adults, use of cannabis products is increasing for the treatment of headaches and migraines  
140 [13]. An observational study reported that 36% of adult cannabis users are using cannabis to  
141 relieve symptoms related to migraine and/or headaches. Further, this study reported that the use  
142 of cannabis products in adults led to an average reduction of 3.6 points on a 10-point intensity of  
143 headache scale [14, 15]. Despite promising observational data in adults, a paucity of literature  
144 exists that demonstrates the tolerability of cannabis for the treatment of chronic headaches in  
145 adolescents. Cannabidiol (CBD) and Tetrahydrocannabinol (THC) are the principal active

146 cannabinoids which have a number of potential therapeutic applications [16]. CBD, which is not  
147 associated with the same intoxicating effects of THC, acts as a negative allosteric modulator of  
148 CB1 receptors in the endocannabinoid system [17]. CBD potentiates anandamide-mediated  
149 intrinsic neurotransmission [18], and has antioxidant and anti-inflammatory activity [19].  
150 Canadian studies have demonstrated the safety and tolerability of CBD-enriched CHE in children  
151 with refractory epilepsy [20, 21]. Huntsman et al reported on the preliminary results of the  
152 CARE-E trial where a 1:20 THC:CBD CHE oil was found to be well tolerated in children, and  
153 THC plasma concentrations were below levels associated with intoxication despite CBD doses of  
154 up to 12 mg/kg per day [21].

155 In Canada, recreational markets have increased cannabis accessibility and there is increasing  
156 interest in managing chronic headaches off-label with cannabinoids, self-guided in the absence  
157 of evidence [22]. The paucity of clinical trial data in children is due to many historical challenges  
158 with studying cannabis products and cannabinoids, resulting from legal difficulties in obtaining  
159 products, variable product quality control and the stigma associated with illegal drug use, and  
160 particularly with children. The current reality warrants the need to conduct robust interventional  
161 studies establishing the tolerability, safety, and efficacy of cannabis in adolescents with chronic  
162 headaches. Here we describe a protocol for CAN-CHA (CANnabis for Chronic Headaches in  
163 Adolescents) trial, an open-label dose escalation study to establish the tolerability of a CBD-  
164 enriched Cannabis Herbal Extract (CHE) in adolescents with chronic headaches. CAN-CHA is  
165 funded by the SickKids Foundation, sponsored by the University of Manitoba and has received  
166 approvals from Health Canada and research ethics board. CAN-CHA is registered with  
167 ClinicalTrials.gov (NCT05337033).

168

169

170 **Methods and analysis**

171 **Primary Objective**

172 To determine the safety and tolerability of escalating doses of a CBD-enriched CHE in  
173 adolescents with chronic headaches.

174 **Secondary Objectives**

- 175 1. To investigate the relationship between the dose-escalation with headache-free days.
- 176 2. To monitor the effect of CBD-enriched CHE oil on the intensity of pain related to chronic  
177 headaches.
- 178 3. To evaluate the effect of CBD-enriched CHE oil on sleep, mood, and function in  
179 adolescents with chronic headaches.
- 180 4. To explore the impact of chronic headaches on quality of life.

181 **Exploratory Objectives**

- 182 1. To investigate the relationship between the dose-escalation and steady-state trough levels  
183 of bioactive cannabinoids/endocannabinoids.
- 184 2. To study pharmacogenetic variations among adolescents receiving CBD-enriched CHE  
185 oil.

186 **Study Population**

187 We will recruit 20 adolescents across three study sites: Halifax, Toronto, and Vancouver. To be  
188 eligible to participate in this study, an individual must meet all of the following criteria:

- 189 1. Adolescents between 14-17 years of age at the time of screening

- 190 2. Diagnosed with Chronic Migraine according to ICHD-3: headache (migraine-like or  
191 tension-type like) occurring on 15 or more days per month for more than 3 months, which  
192 on at least 8 days per month have features of migraine headache [23].
- 193 3. Failed at least two preventive treatment options on the grounds of tolerability and/or  
194 efficacy, including but not limited to antidepressants (tricyclic antidepressant or selective  
195 norepinephrine reuptake inhibitor), magnesium, gabapentin, topiramate, beta-blockers,  
196 memantine, and/or non-pharmacological therapies including nutraceuticals and botox.
- 197 4. Females who have reached menarche must have a negative serum pregnancy test during  
198 screening
- 199 5. Must be willing to engage with psychology and physiotherapy throughout the trial as  
200 appropriate.

201 Adolescents meeting any of the following criteria will be excluded from the study:

- 202 1. As per the investigator judgment, the participant is not an ideal candidate due to a  
203 personal issue or medical condition that is likely to impede in the successful  
204 completion of the study
- 205 2. Participants with a history of post-concussion headache or new daily persistent  
206 headache
- 207 3. Participants with a diagnosis of medication overuse headache
- 208 4. Participants with cardiac, renal, or hepatic disease (assessed by the site investigator)
- 209 5. Participants with complex regional pain syndrome-II
- 210 6. Participants with abnormal ECG findings at baseline (as determined by the  
211 investigator)



- 212 7. Participants who are on the following medications: opioids, antipsychotics, antimanic,  
213 barbiturates, benzodiazepines, muscle relaxants, sedatives, or tramadol
- 214 8. Participants with developmental delay or impairments including autism, cerebral  
215 palsy, or intellectual disability
- 216 9. Participants with a personal or family history of schizophrenia or psychotic disorders
- 217 10. Participants who are/plan to become pregnant within the study period or within three  
218 months of interventional product discontinuation
- 219 11. Participants who cannot commit to using contraception, refraining from recreational  
220 cannabis use and driving throughout the study period

#### 221 **Withdrawal criteria**

222 Study participants may withdraw from the study at any point. If a participant's headaches worsen  
223 or they suffer from intolerable treatment related adverse effects, they will be withdrawn from the  
224 study. Participants who become pregnant during the study period, do not attend follow-up visits,  
225 or do not comply with the prescribed interventional drug regimen will be withdrawn from the  
226 study. Participants will be given the option to only withdraw from the study intervention, these  
227 participants will continue to be followed up for safety assessments till the end of study. All  
228 participants withdrawn from the study will be included in the final report at the end of the study  
229 for transparency.

#### 230 **Intervention**

231 The investigational product for our study is a CBD-enriched CHE, MPL-001, purchased from  
232 MediPharm Labs. MPL-001 is a CBD-enriched CHE where each ml of oil contains 2 mg of THC  
233 and 50 mg of CBD dissolved in coconut/palm-based medium chain triglycerides (MCT) carrier  
234 oil. The MPL-001 (CBD:THC 25:1) oil used in this study contains lemon-peppermint flavoring

235 agents. Manufacturing of MPL-001 occurs following Good Manufacturing Practices includes the  
236 following steps: harvesting of plant, followed by weighting, and drying. Further, dried plants are  
237 subjected to bucking, ethanolic extraction, filtration of cannabinoid ethanolic solution, and  
238 evaporation of ethanol, this leaves over acidic cannabis resin. Subsequently, cannabis resin is  
239 decarboxylated (activated) and mixed with oil. The oil is made available in a glass bottle sealed  
240 with child lock caps, stored and labeled at the study central pharmacy according in accordance  
241 with the *Cannabis Act, 2018* and the Health Canada Division 5 *Food and Drugs Act* [24]. All the  
242 study participants will receive an escalating dose starting at 0.2-0.4 mg/kg of CBD per day with  
243 dose increases (0.2 mg/kg/day increments) happening monthly to a maximum of 0.8-1.0 mg/kg  
244 of CBD per day. This dosing strategy reflects the current clinical practice of study investigators  
245 and well below the maximum dose of CBD-enriched CHE of 10-12 mg/kg/day previously well  
246 tolerated in children with epilepsy [21]. Participants will be provided with dosing calendars (Fig  
247 2) and be instructed to take their daily dose bid with 25% of the dose in the morning and 75% of  
248 the daily dose in the late afternoon to mimic the diurnal variation [25] in the endocannabinoids  
249 and prevents adolescents from having to take cannabis during school hours.

250 **Fig 2.** CAN-CHA dosing calendar.

## 251 **Study design**

252 CAN-CHA is a multicenter, open-label dose-escalation study to determine the tolerability of  
253 MPL-001 in adolescents with treatment refractory chronic migraine. A traditional 3+3 dose  
254 finding design was not practical as all participants would not receive the lowest cannabinoid dose  
255 and the recommended “start low and go slow” approach to titration. The trial will be conducted  
256 in three Canadian centers. CAN-CHA will consist of three different phases: baseline (1 month)  
257 without intervention, treatment (4 months of escalating doses) and weaning (1 month). All

258 participants and their caregivers will be invited to complete a pre- and post-study survey about  
259 their experiences in the trial to inform future research.

### 260 **Patient and public involvement**

261 CAN-CHA trial was designed in collaboration with youth from the KidsCAN Young Persons'  
262 Research Advisory Group (YRPAG) and from the Solutions for Kids in Pain (SKIP) network.  
263 The Canadian Collaborative for Childhood Cannabinoid Therapeutics (C4T) Parent Advisory  
264 Committee provided insight on the outcome measurement tools and the consent form. Three  
265 youth advisors (TL, ZA, MC-G) with chronic migraines have been involved throughout the study  
266 design process and will continue to advise on recruitment strategies, designing materials,  
267 reporting and dissemination.

### 268 **Baseline Phase**

269 Eligible adolescents will be asked by their healthcare providers if they are interested in learning  
270 more about this research study. A study team member, who is not involved in the patients' care,  
271 will present the study, review the consent documents and answer any questions from the patients  
272 and their families. Adolescents who meet the inclusion criteria, assent, and whose caregiver's  
273 consent to participate will then begin a baseline period. Baseline will consist of one month period  
274 without intervention to estimate headache frequency and severity, as well as mood, sleep, and  
275 pain before administering the intervention to the participants. Participants will be asked to  
276 maintain a daily electronic headache diary that will include reporting on the severity of  
277 headaches, associated pain, sleep, absences from work/school and adverse events. Participants  
278 will complete age-validated scales on sleep related impairment, anxiety, depression, positive  
279 mood, pain interference, family impact and goal attainment scaling [26-31] as described in the  
280 Fig 1. A blood sample will be drawn from the study participants to measure liver transaminases

281 (ALT/AST) and creatinine, measure endocannabinoids and detect pregnancies, while saliva will  
282 be sampled for extraction of genomic DNA to allow for genotyping of pharmacogenetic variants.  
283 ECGs (within 3 months of screening or done at the time of screening) will be recorded at  
284 baseline to ensure there are no cardiac electrical activity concerns.

285 **Fig 1.** CAN-CHA schedule of events as per SPIRIT guidelines

## 286 **Treatment Phase**

287 Following the one-month baseline period, study participants will receive CBD-enriched CHE  
288 oil, MPL-001 with a dosing calendar and administration pamphlet shipped directly to their homes  
289 from the trial coordinating centre. A handout on cannabis oil administration co-created with the  
290 youth advisors and will be provided to all study participants and their families that will also have  
291 a video component. There will also be a demonstration by the research coordinator at the first  
292 study visit using olive oil in a product bottle. The study participants will be instructed to  
293 administer the investigational product at a starting dose of 0.2-0.4 mg/kg/day divided into two  
294 doses (BID, 25% in the morning and 75% in the evening after school) each day for one month.  
295 Dose-escalation schedule during the treatment phase is described in Table 1. Participants will  
296 continue to complete a daily electronic headache diary to monitor symptoms and adverse effects.  
297 During all follow up visits, participants and their caregivers will be asked to complete validated  
298 outcome measurement tools alongside the PedsQL™ Family Impact Module assessment, and  
299 Self-directed goal attainment. Blood samples will be collected prior to starting the next dose  
300 level, at study visits and will be used to evaluate changes and variability in cannabinoid  
301 pharmacokinetics with escalating doses, confirm pregnancies, and monitor liver enzymes and  
302 creatinine over time.

303 **Table 1.** Dosing schedule for CAN-CHA evaluating a CBD-enriched CHE from visit 2 to visit 6

304

Visit	CBD total daily dose	Frequency	Duration
Visit 2	0.2-0.4 mg/kg/day	BID	1 month
Visit 3	0.4-0.6 mg/kg/day	BID	1 month
Visit 4	0.6-0.8 mg/kg/day	BID	1 month
Visit 5	0.8-1 mg/kg/day	BID	1 month

305

306 **Weaning Phase:** After the baseline phase (one month, no treatment) and the treatment phase  
307 (four months, escalating doses), participants will start the weaning schedule. Weaning includes  
308 incrementally reducing the dose (by 0.2 mg/kg CBD every week) leading to complete  
309 discontinuation of the study product. The complete weaning schedule is detailed in Table 2. The  
310 intervention will be discontinued by visit 7. If the parents, adolescents, and healthcare providers  
311 feel that there was improvement while on the intervention, participants will discuss the continued  
312 authorization of medical cannabis with the enrolling physician, caregivers and their healthcare  
313 team.

314

315

316

317

318 **Table 2.** The weaning schedule which begins at visit 6 and ends at visit 7

319

Visit 6	CBD total daily dose	Frequency	Duration
Week 1	0.6-0.8 mg/kg/day	BID	7 days
Week 2	0.4-0.6 mg/kg/day	BID	7 days
Week 3	0.2-0.4 mg/kg/day	BID	7 days
Week 4	0 mg/kg/day	BID	7 days

320

### 321 **Dosing rationale and calculations**

322 Data on the pharmacokinetics related to cannabinoids in adolescents are extremely lacking. In  
323 the current study, the CBD dose is extrapolated from safety data obtained in clinical trials in  
324 children and adults with refractory epilepsy [32-38]. CBD was found to be safe and well-  
325 tolerated in children with refractory epilepsy at a dose of up to 20 mg/kg/day [32, 33, 35, 38, 39].  
326 We aim to keep the CBD dose as low as possible to limit adverse events and reduce costs for  
327 families should we confirm a tolerable dose is effective in future randomized controlled trials.  
328 The use of THC is associated with some risk of developing adverse effects of the central nervous  
329 system, [40, 41] however, THC possesses its central pain-relieving potential at very low doses,  
330 much lower than would be expected from recreational cannabis exposures [42]. Previous studies  
331 on a 1:20 THC:CBD CHE oil in children reported that plasma THC levels following doses of up  
332 to 12 mg/kg/day suggested a low risk for THC intoxication [21]. The quantity of THC in our  
333 study product is 1 mg per mL with maximum THC doses only reaching 0.05 mg/kg/day, which  
334 we do not expect to be associated with any adverse psychoactive reactions. In this study, the  
335 maximum dose of CBD will be less than 10 percent of the recommended dose of CBD in the  
336 previous studies conducted in the pediatric population [43]. In order to maintain the accuracy and

337 consistency in the dosing regimen of study participants across all the study centers, the mid-point  
338 of the dose range will be selected to calculate the desired dose based upon the weight of the  
339 participants. Participants will be weighed at each study visit to assist in tracking changes in  
340 appetite; however, the dose calculation will be based on the weight taken at baseline. The final  
341 dose will be calculated by rounding off (0.5 mL of MPL-001). This will help in achieving  
342 improved precision and will ease administration of the investigational product to the study  
343 participants. For example, an adolescent weighing 50 kg will receive a starting total daily dose  
344 containing 15 mg of CBD (0.3 mg/kg/day) and take 4 mLs in the morning and 11 mLs in the  
345 afternoon.

346

#### 347 **Dose limiting toxicities (DLTs)**

348 Adverse events will be categorized using the Common Terminology Criteria for Adverse Events  
349 (CTCAE version 5.0 dated 27 Nov 2017). If any of the following DLTs occur the participant will  
350 not move up to the next dose level. Dose escalations will not be reattempted but the participant  
351 shall remain in CAN-CHA should no other DLTs occur. DLTs include:

- 352 1. Parental/youth report complaints of moderate mood elevation defined as exaggerated  
353 feelings of well-being which is disproportionate to the events and stimuli (Euphoria  
354 Grade 2)
- 355 2. Somnolence Grade 2 which includes moderate sedation (sleepiness and drowsiness) that  
356 limits instrumental activities of daily living
- 357 3. Cannabis-attributed diarrhea, Grade 2 or more defined as an increase of 4 - 6 stools per  
358 day over baseline; moderate increase in ostomy output compared to baseline; limiting  
359 instrumental activities of daily living

- 360 4. Unexplained tachycardia (w/out pain, fever, anemia etc.) requiring medical intervention
- 361 5. Unexplained hypotension requiring medical intervention
- 362 6. Non-infectious conjunctivitis Grade 2 defined as moderate decrease in visual acuity (best
- 363 corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known
- 364 baseline) characterized by inflammation, swelling and redness to the conjunctiva of the
- 365 eye.
- 366 7. Serious adverse events requiring hospitalization
- 367 8. Discretion of the participant, physician, or parents

368

369 **Primary Outcome**

370 The frequency and type of cannabis-related adverse events among study participants will be

371 assessed daily throughout the study. Adverse events will be reported daily and reviewed at study

372 visits.

373

374 **Secondary Outcomes**

- 375 1. The frequency of headache measured using headache-free days [assessed: daily throughout
- 376 the study]. Reported number of headache-free days per month during the study period
- 377 2. The average intensity of pain due to chronic headaches as measured using an 11-point
- 378 Numeric Rating Scale (NRS) [assessed: daily throughout the study] [44]. Reported for
- 379 each study as a percentage change in average daily pain intensity due to chronic headaches
- 380 on the numeric rating scale (NRS) from baseline to each follow up visit



- 381 3. The impact of pain on participants' quality of life using the PROMIS Pediatric Pain  
382 Interference– Short Form 8a [assessed: at visits 1,2,3,4,5,6 and 7] [26]. Reported as a  
383 percentage change in the scores from baseline value
- 384 4. The quality of sleep will be recorded using the PROMIS Pediatric Sleep-Related  
385 Impairment– Short Form 8a scale [45]. [assessed: at visits 1,2,3,4,5,6 and 7] Reported as a  
386 percentage change in scores from baseline value
- 387 5. Changes in anxiety will be measured using the PROMIS Pediatric Short Form v2.0 -  
388 Anxiety - 8a scale [46] [assessed: at visits 1,2,3,4,5,6 and 7]. Reported as percentage  
389 change in scores from the baseline value
- 390 6. Change in mood will be evaluated using two tools PROMIS Pediatric Short Form v2.0 -  
391 Depressive Symptoms 8a scale and the PROMIS Pediatric Positive Affect – Short Form 8a.  
392 [29, 47] [assessed: at visits 1,2,3,4,5,6 and 7]. Reported as a percentage change in scores  
393 from baseline value
- 394 7. Change in self-directed goal attainment (participant and parent reported) [assessed: monthly  
395 throughout the study] [30]. Reported as a percentage toward a physical, mental and social  
396 by participant at each monthly visit
- 397 8. Change in scores of PedsQL™ Family Impact Module, Version 2.0 [assessed: monthly  
398 throughout the study] [31]. Reported as percentage change in scores from the baseline  
399 value
- 400 9. Steady-state trough plasma levels of bioactive cannabinoids THC, CBD, 11-OH-THC, 7-  
401 OH-CBD, and endocannabinoids [assessed: monthly throughout the study]. Reported as a  
402 plasma concentration relative to each dose increase/decrease and according to genotype

403 10. Genetic polymorphisms within genes encoding for cytochrome P450 enzymes and the p-  
404 glycoprotein transporter and their association with plasma levels of THC, CBD, and their  
405 active metabolites in the study participants

#### 406 **Assessments**

407 Participants will be enrolled in the study for six months. De-identified participant data will be  
408 collected electronically in a Research Electronic Data Capture (REDCap) database or paper  
409 copies will be provided based on participants' preferences. Assessments completed on paper will  
410 be kept as source documents at each study site and entered into REDCap by study staff. The  
411 following includes a detailed description of all planned assessments.

#### 412 **Physical examination**

413 During the baseline and close out visits (visit 7), participants will undergo physical assessments,  
414 but weight will be reported at every visit to potentially signal changes in appetite. Blood work  
415 will assess liver function and renal safety, plasma concentration of cannabinoids, and pregnancy  
416 status. At the time of screening, participants will receive an electrocardiogram as per standard  
417 practice at each site should they not have had one in the previous 3 months.

#### 418 **Electronic headache diary**

419 The daily diary was developed in collaboration with the youth advisors as described above.  
420 Administration will incorporate best practices in the use of daily diaries in adolescents, and  
421 feedback from patients with chronic pain and families interviewed about the use of in-home  
422 longitudinal ecological momentary assessment tools [48]. The purpose of the diary is to monitor  
423 and report headache characteristics, including intensity (Numeric Rating Scale; NRS), headache-  
424 free days, use of the rescue medication, and potential headache triggers (e.g., low sleep).  
425 Electronic diaries will be completed by the participants using REDCap. Adverse events will be

426 assessed daily with flags to research coordinators to review changes. The NRS is a validated tool  
427 that will be used to record daily self-reports of headache intensity from visit 1 until the end of the  
428 study [49]. Participants will rate the intensity of pain from 0 to 10, 0 means no hurt, 10 means the  
429 worst hurt you could ever imagine. The efficacy of the investigational product in treating the  
430 chronic headaches will be assessed in reducing the intensity of headache from baseline to each  
431 follow-up visit. Daily data from the electronic headache diaries will be transferred to the server.  
432 Based on pain intensity reported on the NRS, the study participant will be categorized into the  
433 severity of the headaches. Mild headache will vary in intensity between 1-5, moderate between  
434 6-8, and severe between 9-10 [50]. A complete list of the daily headache diary questions are  
435 provided in Table 3. All the study participants will be given an option of using an electronic  
436 wrist worn device (actigraphy), provided at no cost to them by the study team, to help keep track  
437 of the number of hours slept per night.

438 **Table 3:** Electronic daily headache diary questions

1.	How many hours did you sleep last night?
2.	Did you have anything to eat before taking your first dose of the study medication?
3.	Did you take both doses of study medication today? If no, tell us why not? (open text)
4.	Did you have any headaches today?
5.	Rate your baseline/average pain level today, on a scale from 0-10

6.	Rate your <b>highest</b> pain level today, on a scale from 0-10
7.	Rate your <b>lowest</b> pain level today, on a scale from 0-10
8	Did you take any other medications today for any reason? If yes, please list the medication and frequency. For example, Tylenol – 3 regular strength tabs.
9.	Did you avoid attending any events (school/extracurricular/social) today due to headaches?
10.	Did your parent(s) or caregiver miss/avoid attending events (work/extracurricular/social) today due to your headache?
11.	Did you see physiotherapist or psychologist today?
13.	Did you experience any of the following symptoms today? (checklist) nausea, vomiting, diarrhea, drowsiness, fatigue, sleepiness, seizures or convulsions, decreased appetite, increased appetite, dizziness, dry mouth, irritability, something else (open text)
14.	Is there anything else you would like to share with us about your day? (open text)

439

440

441

442 **PROMIS measures**

443 Patient-Reported Outcomes Measurement Information System (PROMIS) evaluates social,

444 mental, and physical health of adults and children [51]. We will be using the PROMIS tools to

445 measure pain interference, sleep, depressive symptoms, emotions, and family's quality of life.

446 These tools will be completed by the study participants. The following PROMIS measure will be

447 administered by the study participants.

448 **Pediatric Pain Interference - Short Form 8a scale**

449 The Pediatric Pain Interference PROMIS tool assesses the self-reported consequences of pain on

450 the essential aspects of a participant's life. It measures the extent to which pain interferes with

451 cognitive, emotional, social, physical, and recreational activities. The pediatric pain interference

452 scale is non-disease specific, and the items utilize a 7-day recall period (items include the phrase

453 "the past 7 days"). Varni et al. describe the strong psychometric properties of the PROMIS

454 Pediatric Pain Interference Scale [26].

455 **Pediatric Sleep-Related Impairment - Short Form 8a scale**

456 The Pediatric Sleep-related Impairment is a PROMIS tool, which assesses perceptions of

457 sleepiness during awake hours and sleep-related impairments during the day. Mainly this tool

458 assesses sleepiness during the daytime, sleep offset, and its impact on cognition, other daily

459 activities, as well as emotional impact. The Pediatric Sleep-Related Impairment - Short Form 8a

460 scale has demonstrated good validity and internal consistency [27].

461 **Pediatric Depressive Symptoms - Short Form 8a scale v2.0**

462 Pediatric Short Form v2.0 - Depressive Symptoms 8a is a PROMIS tool which is used for

463 assessment of negative mood states, including sadness or guilt, self-criticism, self-perceived

464 worthlessness, loneliness, interpersonal alienation (social cognition) and decreased positive

465 affect and engagement. However, this scale does not assess somatic symptoms associated with

466 depression, such as changes in appetite and sleeping patterns. Pediatric Short Form v2.0 -

467 Depressive Symptoms 8a scale has demonstrated good test-retest reliability, and validity of  
468 administration across groups [28].

#### 469 **Pediatric Positive Affect – Short Form 8a scale**

470 The Pediatric Positive Affect scale is PROMIS tool used for the assessment of positive or  
471 rewarding feelings and moods, including elation, pride, affection, pleasure, joy, engagement,  
472 excitement, happiness, and contentment. The short form of Pediatric Positive Affect scale is an  
473 efficient, accurate, and valid assessment of positive affect in adolescents and good reliability has  
474 been reported [47].

#### 475 **Pediatric Anxiety Symptoms- Short Form 8a scale v.2.0**

476 The pediatric short form v2.0 Anxiety scale is a PROMIS tool used to assess the self-reported  
477 fear (fearfulness, panic), anxious misery (worry, dread), hyperarousal (tension, nervousness,  
478 restlessness), and somatic symptoms related to arousal (racing heart, dizziness). The literature  
479 reports excellent reliability and validity of the Pediatric Short Form v2.0 - Anxiety - 8a scale  
480 [29].

#### 481 **Goal attainment Scaling**

482 Goal attainment scaling is a patient-derived and reported outcome measure in which participants  
483 select their goals in areas where they would like to improve function [30]. Participants will be  
484 asked to select three goals at their screening appointment which could include physical, social,  
485 academic, or personal goals that they hope to improve on throughout the study period. In this,  
486 scaling goals are weighted with the importance (on a 0-10 scale) and difficulty (also on a 0-10  
487 scale).

#### 488 **PedsQL™ Family Impact Module**

489 Pediatric quality of life family impact module aims to measure the effect of the child's chronic  
490 health condition on the family and parents. The PedsQL examines the domains of physical,  
491 emotional, social, cognitive, worry and communication to provide an overview of quality of life  
492 and impact on families. The PedsQL scale has demonstrated well defined validity and reliability  
493 [31].

#### 494 **Cannabinoid and metabolite assessment**

495 To establish the relationship between dose-escalation and steady-state trough plasma  
496 concentrations ( $C_{ss}$ ,  $M_{in}$ ) of the bioactive cannabinoids, we will collect blood samples before  
497 each dose escalation. At the first visit the study nurse will ask participants what methods they  
498 would like to employ to reduce needle pain. They will be offered evidence-based strategies  
499 including distraction and breathing techniques, use of a topical anesthetic and preferred  
500 positioning for blood draws [52]. Cannabinoid levels will be assessed using a previously  
501 described Liquid Chromatography-Mass Spectrometry (LC-MS/MS) method validated as per US  
502 FDA guidelines [53]. The blood sample from the study participants will be drawn into the  
503 heparinized lithium Barricor vacutainers® (BD Canada, Mississauga, ON). The collected blood  
504 will be centrifuged for 10 minutes at 1500 rpm to separate the plasma from the blood. The  
505 separated plasma will be stored at  $-80^{\circ}\text{C}$  until analysis. An LC-MS/MS method will be used to  
506 quantify the plasma concentration of THC, CBD, 11-OH-THC, 7-OH-CBD, and  
507 Cannabichromene. Stock solutions of cannabinoids and their respective stable isotope-labeled  
508 internal standards (Cerilliant Corp., Round Rock, TX) will be prepared in methanol at 1 mg/mL  
509 and stored at  $-20^{\circ}\text{C}$  until use. Stock solutions will be serial diluted using blank human plasma to  
510 develop calibration curves. Low, medium, and high-quality control (QC) samples will determine  
511 acceptance of the analytical run. QC and calibration samples will be prepared fresh each day

512 samples are analyzed. Calibration curves will be constructed from a plot of the peak area ratios  
513 of the cannabinoid and its respective internal standard against the nominal concentration. The  
514 linearity of the calibration curves will be determined with a linear least-squares regression  
515 analysis using  $1/X$  as a weighting factor. Using FDA bioanalytical guidance, all calibration  
516 curves will be linear ( $r^2 > 0.99$ ) and intra- and inter-day precision and accuracy will be within  
517 15%, except at the limit of quantification which will need to be within 20%. For all QC samples  
518 for a given run calculated concentrations will be within 15% of their nominal values. The plasma  
519 sample extraction will involve addition of internal standard working solution (10  $\mu$ L) followed  
520 by protein precipitation with cold acetonitrile and removal of lipids using Agilent Captiva EMR-  
521 Lipid well plates. Supernatant will be transferred to borosilicate tubes and dried under filtered air  
522 for 30 minutes at 37°C. Samples will be reconstituted with 200  $\mu$ L mobile phase and 100  $\mu$ L  
523 transferred into HPLC inserts, 5  $\mu$ L will be further injected onto an Agilent Phenyl-hexyl small-  
524 bore (2.1  $\times$  12.5 mm, 5  $\mu$ m) column and guard column maintaining the column temperature at  
525 30°C to separate cannabinoids. Mobile phase A (water containing 0.1 mM ammonium formate)  
526 and B (methanol containing 0.1 mM ammonium formate) will separate the cannabinoids using a  
527 10 minute gradient method with a flow rate of 250  $\mu$ L/min. Positive ion mode electrospray  
528 ionization (ESI), with an ion spray voltage of 5500 V, will be used to conduct multiple reaction  
529 monitoring (MRM) for quantification of CBD (quantifier ion  $m/z$  315.1>193.2; qualifier ion  $m/z$   
530 315.1>259.2), THC (quantifier ion  $m/z$  315.1>193.1; qualifier ion  $m/z$  315.1>259.2), 11-OH-  
531 THC (quantifier ion  $m/z$  331.1>193.1; qualifier ion  $m/z$  331.1>201.0), CBC (quantifier ion  $m/z$   
532 315.1>193.2; qualifier ion  $m/z$  315.1>259.2), CBD-d3 (318.2>196.1), THC-d3 (318.2>196.1),  
533 11-OH-THC-d3 (334.2>196.1), and CBC-d9 (324.3>202.2) using a ABSciex 6500 QTRAP mass  
534 spectrometer (ABSciex, Concord, ON, Canada) and MultiQuant 3.0.1 Software. The



535 temperature, gas source 1, gas source 2, curtain gas, entrance potential, and collision activated  
536 dissociation gas were set to 600°C, 70, 60, 50, 10 V, and 10, respectively.  
537 The experienced team at the Cannabis Research Initiative of Saskatchewan, University of  
538 Saskatchewan will conduct all the analyses of the samples collected from all the three study sites.  
539 The samples will be analyzed in the three batches starting within the three months of the  
540 collections. The stability analysis of cannabinoids stored at -80°C for three months indicates  
541 excellent stability as described previously [20].

#### 542 **Pharmacogenomic analyses**

543 Genomic DNA will be extracted from saliva samples using a QIAmp DNA extraction kit at the  
544 University of Manitoba and genotyping will be performed using the Illumina Global Screening  
545 Array (GSA) v3 array on the iScan array scanner. The GSAv3 GWAS arrays have been designed  
546 to capture both common and rare genetic variation, including all variants that have been shown  
547 by the Clinical Pharmacogenetics Implementation Consortium to affect the function of the  
548 selected candidate genes [54]. Genotyped variants and samples will undergo standard quality  
549 control procedures in PLINK 1.9 [55]. Imputation of non-genotyped variants will be performed  
550 using the Michigan Imputation Server, including the Haplotype Reference Consortium data as a  
551 reference and genetically-determined ancestry will be assessed with EIGENSOFT v5 [56].  
552 Association between these variants and response outcomes will be performed using logistic  
553 regression.

#### 554 **Health care utilization**

555 Costs are an important consideration for families caring for an adolescent with a chronic illness,  
556 and are especially concerning for families accessing cannabis oils [57]. Participants in this study  
557 will provide consent to access their administrative health records for a pre and post study of

558 healthcare utilization to be designed, reviewed and approved in the future. During CAN-CHA,  
559 measures of absences from school and work for participants and caregivers, hospitalizations and  
560 the use of rescue medicines will be captured to inform building blocks for future health  
561 technology assessment. To reduce participant burden, access to health records will also ensure  
562 that the use of all rescue medications is documented should there be an admission to the  
563 emergency department or inpatient unit.

#### 564 **Sample size**

565 CAN-CHA is a tolerability study, designed to evaluate the safety of escalating doses of a  
566 cannabidiol-enriched CHE. Given the within-participant study design, a sample size of 20 study  
567 participants (common for early phase trials) should provide a reasonable characterization of the  
568 pattern of adverse event frequency and severity as dosing increases. To provide more  
569 generalizable data we will recruit these participants across three pediatric chronic pain/headache  
570 programs in Halifax, Vancouver, and Toronto, Canada.

#### 571 **Data collection, management and sharing**

572 Data collection will be the responsibility of the study team at each site under the supervision of  
573 the site investigators (TFO, ECL, GAF) and trial sponsor (LEK, University of Manitoba).  
574 Investigators and research coordinators will be responsible for ensuring the accuracy,  
575 completeness, legibility, and timeliness of the data reported. All source documents will be  
576 completed in a neat, legible manner to ensure accurate interpretation of data. Hardcopies of the  
577 study visit measurement tool will be provided as source documents for each participant enrolled  
578 in the study. Data recorded in the electronic case report form (eCRF) derived from source  
579 documents should be consistent with source documents. Clinical and laboratory data will be  
580 entered into REDCap (Research Electronic Data Capture), [58] a 21 CFR Part 11-compliant data

581 capture system provided by the Women and Children's Health Research Institute at the  
582 University of Alberta, Edmonton. REDCap includes password protection and internal data  
583 quality checks, such as automatic range checking, to identify data that appear inconsistent,  
584 incomplete, or inaccurate to the study team for verification. Clinical data will be entered directly  
585 from the source documents. Full de-identified datasets will be available from the corresponding  
586 author upon reasonable request and review by the trial steering committee.

### 587 **Statistical analysis**

588 The primary statistical analyses will be a descriptive summary of the pattern of incidence and  
589 severity of adverse events across dosage levels. Adverse event severity grading is assigned using  
590 CTCAE definitions as described above. Conventional summary statistics will be used to describe  
591 baseline characteristics and other outcomes (means, standard deviations, as well as medians,  
592 range, and interquartile range (IQR) for numerical variables; counts and percentages for  
593 categorical variables). Adverse events will be reported overall (duration of the study period) and  
594 by dosage level (study month). Medians, ranges and IQR will be provided for the concentrations  
595 of CBD, THC, and the major metabolites at each sampling point. The ratio of concentration of  
596 parent compound to metabolites and endocannabinoids will also be summarized to explore  
597 variability in cannabinoid metabolism. Severity, frequency, and relationship of treatment  
598 emergent AEs to study intervention will be presented by system organ class and MEDRa coded.  
599 All serious adverse events will be reported to pharmacovigilance programs including Health  
600 Canada and the Canadian Paediatric Surveillance Program along with regulatory bodies  
601 including research ethics boards, the data safety monitoring board and trial steering committee.  
602 The secondary outcomes including pain, sleep impairment, depression, positive affect, anxiety,  
603 and goal attainment scores will be summarized at each timepoint; within-participant change from

604 baseline of these measures will also be summarized (both absolute and percentage change) but  
605 this trial is underpowered, and not designed to evaluate efficacy.

### 606 **Ethics and dissemination**

607 CAN-CHA received a No Objection Letter from Health Canada (Dec 2022), registered with  
608 ClinicalTrials.gov (NCT05337033). The study was approved by the University of Manitoba  
609 Health Research Ethics Board (HS25503- B2022:037. An institutional cannabis research license  
610 is received in Sep 2022, and we expect to enroll our first participant in Spring 2023. Written  
611 informed consent will be taken from all the participants and from the legal guardians for the  
612 participants who will be below 16 years of age. We plan to disseminate our findings of the CAN-  
613 CHA trial by presenting them to conferences and publishing them in an open-access journal.

### 614 **Discussion**

615 In Canada, adolescents with refractory headache disorders are using cannabis products off-label  
616 to manage their symptoms, self-guided in the absence of evidence [59]. Chronic headaches are  
617 often resistant to standard drug therapies in adolescents, resulting in school absenteeism,  
618 withdrawal from social activities and can cause significant stress for families [60]. Based on  
619 anecdotal reports, parents of children with chronic headaches found cannabinoids to be effective  
620 for the management of headache[1], but there remains minimal data available to inform dosing  
621 or safety. CAN-CHA is a tolerability study designed with youth and parents that will investigate  
622 the safety of escalating doses up to 1mg/kg/day of CBD-enriched CHE in adolescents. This  
623 represents the first study evaluating a cannabis product, providing valuable knowledge on the  
624 safety and dosing of a CBD-enriched CHE in children with chronic pain. The CAN-CHA trial is  
625 an open label with a small sample size, underpowered to evaluate efficacy. This study will  
626 inform dose selection for a larger scale randomized clinical trial comparing a CBD-enriched

627 CHE oil to placebo (on top of standard of care) for adolescents with chronic headache. Given the  
628 high prevalence of chronic headaches, severe morbidity, and current lack of effective treatment  
629 options, the successful outcomes from this research project will have the potential to create  
630 meaningful impact for the lives of Canadian adolescents.

### 631 **Supporting information**

632 **S1.** SPIRIT checklist: Recommended items to address in a clinical trial protocol and related  
633 documents.

634 **S2.** Approval by ethics committee.

635 **S3.** Study protocol reviewed by ethics committee.

### 636 **Abbreviations**

637 AE: Adverse Events; BMI: Body Mass Index; CBD: Cannabidiol; CHE: Cannabis Herbal  
638 Extract; CNS: Central Nervous System; eCRF: electronic case report form; GMP: Good  
639 Manufacturing Practices; NRS: Numeric Rating Scale; NSAIDs: Non-steroidal Anti-  
640 inflammatory Drugs; REDCap: Research Electronic Data Capture; THC: delta 9 –  
641 Tetrahydrocannabinol

### 642 **Ethics and dissemination**

643 The study was approved by the University of Manitoba Health Research Ethics Board  
644 (HS25503- B2022:037). We plan to disseminate our findings of the CAN-CHA trial open-access  
645 publication.

### 646 **Author's contributions**

647 LEK is the principal Investigator; led the proposal and protocol development. ECL, GAF, and  
648 TFO are the qualified investigators contributed to study design and to development of the  
649 proposal. TL, ZA, MCG, are the youth research partners, RB is biostatistician, BS is trial

650 coordinator, and MC is PhD trainee; drafted and revised manuscript. All authors provided  
651 insights in study design, read, and approved the final manuscript.

### 652 **Availability of data and material**

653 Access to the protocol and a deidentified dataset may be provided upon reasonable request to  
654 **LEK** and approval by the Clinical Trial Steering Committee.

### 655 **Funding**

656 This work was supported by the Hospital for Sick Children Foundation and the Canadian  
657 Institutes of Health Research grant number N120-1028. An investigational product for this trial  
658 has been purchased from MediPharm Labs. This organization has played no role in the design,  
659 conduct or reporting of the trial.

### 660 **Competing interest**

661 **LEK** is the Scientific Director for The Canadian Collaborative for Childhood Cannabinoid  
662 Therapeutics (C4T) academic research team. She holds funding from the Canadian Institutes of  
663 Health Research, Canadian Cancer Society, Research Manitoba, the Sick Kids Foundation, the  
664 Children's Hospital Research Institute of Manitoba, the University of Manitoba and a Mitacs  
665 Accelerate award in partnership with Canopy Growth. Dr. Kelly is also a member of the  
666 Scientific Advisory Board for Health Products Containing Cannabis at Health Canada and a  
667 member of the Board of Directors of the Canadian Consortium for the Investigation of  
668 Cannabinoids (CCIC). **RJH** is a clinical lead for both the Cannabinoid Research Initiative of  
669 Saskatchewan and C4T. He is developing a research protocol in which cannabis products will be  
670 supplied in kind by JMCC Corporation. He is a co-chair of the Scientific Advisory Committee  
671 for Health Products Containing Cannabis at Health Canada. **KEB's** time is supported by a

672 fellowship from the Canadian Child Health Clinician Scientist Program, and she currently holds  
673 unrelated funding from the Society of Pediatric Psychology, BC Children's Hospital Research  
674 Institute, Canadian Institutes of Health Research, ZonMw: The Netherlands Organization for  
675 Health Research and Development, and the CHILD-BRIGHT Network. **ECL** has received  
676 speaking honoraria from Spectrum Therapeutics, Biome Grow, MedReleaf and Miravo  
677 Healthcare. He holds a non-salaried position as the Chief Medical Advisor for the JMCC Group.  
678 He is the Vice President of Neurology Services for Numinus, a psychedelic medicine treatment  
679 and research company. He is a member of the Expert Committee of the Medical Cannabis  
680 Clinicians Society (MCCS) in the United Kingdom and sits on the Advisory Councils for  
681 Cannabis Patient Advocacy & Support Services (CPASS) and MedCan. **SLI** In the last 12  
682 months, Dr. Irwin has received honoraria for authoring a chapter for the Canadian Pharmacy  
683 Association (CPhA) and for doing an online lecture for NeuroDiem. She also receives  
684 compensation for scientific consulting (Impel NeuroPharma Inc, Biohaven Pharmaceuticals and  
685 Lundbeck A/S) and has had research support from the Duke Clinical Research Institute. **MC** has  
686 been granted the 2022 Research Manitoba-George & Fay Yee Centre for Healthcare Innovation  
687 in Health Research PhD Studentship Award. **RB, BS, TL, ZA, MCG, BID, GEB, KAB, VWLT,**  
688 **DP, AGW, ES, EP, ARM, SM, ZZ, SB, SG, JA, TFO, and GAF** have no potential conflict of  
689 interest to declare.

690 **Acknowledgements:** We are thankful to Dr Thierry Lacaze-Masmoniteil for providing insights  
691 during the design of the study and all of the C4T members who have been consulted on protocol  
692 development and mentorship.

## 693 **References**

694 1. Seshia SS, Wang SJ, Abu-Arafeh I, Hershey AD, Guidetti V, Winner P, et al. Chronic  
695 daily headache in children and adolescents: a multi-faceted syndrome. *Can J Neurol Sci.*



- 696 2010;37(6):769-78. Epub 2010/11/10. doi: 10.1017/s0317167100051428. PubMed PMID:  
697 21059537.
- 698 2. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, et al. The global burden  
699 of headache: a documentation of headache prevalence and disability worldwide. *Cephalalgia*.  
700 2007;27(3):193-210. Epub 2007/03/27. doi: 10.1111/j.1468-2982.2007.01288.x. PubMed PMID:  
701 17381554.
- 702 3. Castillo J, Muñoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic  
703 daily headache in the general population. *Headache*. 1999;39(3):190-6. Epub 2004/12/23. doi:  
704 10.1046/j.1526-4610.1999.3903190.x. PubMed PMID: 15613213.
- 705 4. Lantéri-Minet M, Auray JP, El Hasnaoui A, Dartigues JF, Duru G, Henry P, et al.  
706 Prevalence and description of chronic daily headache in the general population in France. *Pain*.  
707 2003;102(1-2):143-9. Epub 2003/03/07. doi: 10.1016/s0304-3959(02)00348-2. PubMed PMID:  
708 12620605.
- 709 5. Grande RB, Aaseth K, Gulbrandsen P, Lundqvist C, Russell MB. Prevalence of primary  
710 chronic headache in a population-based sample of 30- to 44-year-old persons. The Akershus  
711 study of chronic headache. *Neuroepidemiology*. 2008;30(2):76-83. Epub 2008/02/16. doi:  
712 10.1159/000116244. PubMed PMID: 18277081.
- 713 6. Law EF, Palermo TM, Zhou C, Groenewald CB. Economic Impact of Headache and  
714 Psychiatric Comorbidities on Healthcare Expenditures Among Children in the United States: A  
715 Retrospective Cross-Sectional Study. *Headache*. 2019;59(9):1504-15. Epub 2019/09/15. doi:  
716 10.1111/head.13639. PubMed PMID: 31520418; PubMed Central PMCID: PMC6818708.
- 717 7. Bellini B, Arruda M, Cescut A, Saule C, Persico A, Carotenuto M, et al. Headache and  
718 comorbidity in children and adolescents. *J Headache Pain*. 2013;14(1):79. Epub 2013/09/26.  
719 doi: 10.1186/1129-2377-14-79. PubMed PMID: 24063537; PubMed Central PMCID:  
720 PMC6818708.
- 721 8. Pardutz A, Schoenen J. NSAIDs in the Acute Treatment of Migraine: A Review of  
722 Clinical and Experimental Data. *Pharmaceuticals (Basel)*. 2010;3(6):1966-87. Epub 2010/06/17.  
723 doi: 10.3390/ph3061966. PubMed PMID: 27713337; PubMed Central PMCID:  
724 PMC6818708.
- 725 9. Ravishankar K, Chakravarty A, Chowdhury D, Shukla R, Singh S. Guidelines on the  
726 diagnosis and the current management of headache and related disorders. *Ann Indian Acad*  
727 *Neurol*. 2011;14(Suppl 1):S40-59. Epub 2011/08/19. doi: 10.4103/0972-2327.83100. PubMed  
728 PMID: 21847329; PubMed Central PMCID: PMC6818708.
- 729 10. Oermann CM, Retsch-bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB,  
730 et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam  
731 lysine in cystic fibrosis. *Pediatric Pulmonology*. 2010;45(11):1121-34. doi:  
732 <http://dx.doi.org/10.1002/ppul.21301>.
- 733 11. Kacperski J, Kabbouche MA, O'Brien HL, Weberding JL. The optimal management of  
734 headaches in children and adolescents. *Ther Adv Neurol Disord*. 2016;9(1):53-68. Epub  
735 2016/01/21. doi: 10.1177/1756285615616586. PubMed PMID: 26788131; PubMed Central  
736 PMCID: PMC6818708.
- 737 12. Lochte BC, Beletsky A, Samuel NK, Grant I. The Use of Cannabis for Headache  
738 Disorders. *Cannabis Cannabinoid Res*. 2017;2(1):61-71. Epub 2017/09/02. doi:  
739 10.1089/can.2016.0033. PubMed PMID: 28861505; PubMed Central PMCID:  
740 PMC6818708.
- 741 13. Salazar CA, Tomko RL, Akbar SA, Squeglia LM, McClure EA. Medical Cannabis Use  
742 among Adults in the Southeastern United States. *Cannabis*. 2019;2(1):53-65. Epub 2019/03/01.  
743 PubMed PMID: 30815638; PubMed Central PMCID: PMC6818708.
- 744 14. Rhyne DN, Anderson SL, Gedde M, Borgelt LM. Effects of Medical Marijuana on  
745 Migraine Headache Frequency in an Adult Population. *Pharmacotherapy*. 2016;36(5):505-10.  
746 Epub 2016/01/11. doi: 10.1002/phar.1673. PubMed PMID: 26749285.



- 747 15. Cuttler C, Spradlin A, Cleveland MJ, Craft RM. Short- and Long-Term Effects of  
748 Cannabis on Headache and Migraine. *J Pain*. 2020;21(5-6):722-30. Epub 2019/11/13. doi:  
749 10.1016/j.jpain.2019.11.001. PubMed PMID: 31715263.
- 750 16. Gonçalves J, Rosado T, Soares S, Simão AY, Caramelo D, Luís Â, et al. Cannabis and  
751 Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and  
752 Analytical Determination. *Medicines (Basel)*. 2019;6(1). Epub 2019/03/01. doi:  
753 10.3390/medicines6010031. PubMed PMID: 30813390; PubMed Central PMCID:  
754 PMCPMC6473697.
- 755 17. Morales P, Goya P, Jagerovic N, Hernandez-Folgado L. Allosteric Modulators of the  
756 CB(1) Cannabinoid Receptor: A Structural Update Review. *Cannabis Cannabinoid Res*.  
757 2016;1(1):22-30. Epub 2016/01/01. doi: 10.1089/can.2015.0005. PubMed PMID: 28861476;  
758 PubMed Central PMCID: PMCPMC5576597.
- 759 18. Pertwee RG. Pharmacology of cannabinoid receptor ligands. *Curr Med Chem*.  
760 1999;6(8):635-64. Epub 1999/09/02. PubMed PMID: 10469884.
- 761 19. Benito C, Tolón RM, Pazos MR, Núñez E, Castillo AI, Romero J. Cannabinoid CB2  
762 receptors in human brain inflammation. *Br J Pharmacol*. 2008;153(2):277-85. Epub 2007/10/16.  
763 doi: 10.1038/sj.bjp.0707505. PubMed PMID: 17934510; PubMed Central PMCID:  
764 PMCPMC2219537.
- 765 20. Reithmeier D, Tang-Wai R, Seifert B, Lyon AW, Alcorn J, Acton B, et al. The protocol for  
766 the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1  
767 dosage escalation study. *BMC Pediatr*. 2018;18(1):221. Epub 2018/07/10. doi: 10.1186/s12887-  
768 018-1191-y. PubMed PMID: 29981580; PubMed Central PMCID: PMCPMC6035794.
- 769 21. Huntsman RJ, Tang-Wai R, Alcorn J, Vuong S, Acton B, Corley S, et al. Dosage Related  
770 Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic  
771 Encephalopathy: Preliminary Results of the CARE-E Study. *Front Neurol*. 2019;10:716. Epub  
772 2019/07/25. doi: 10.3389/fneur.2019.00716. PubMed PMID: 31333569; PubMed Central  
773 PMCID: PMCPMC6616248.
- 774 22. Rieder MJ. Is the medical use of cannabis a therapeutic option for children? *Paediatr*  
775 *Child Health*. 2016;21(1):31-4. Epub 2016/03/05. doi: 10.1093/pch/21.1.31. PubMed PMID:  
776 26941559; PubMed Central PMCID: PMCPMC4758425.
- 777 23. Headache Classification Committee of the International Headache Society (IHS) The  
778 International Classification of Headache Disorders, 3rd edition. *Cephalalgia*. 2018;38(1):1-211.  
779 Epub 2018/01/26. doi: 10.1177/0333102417738202. PubMed PMID: 29368949.
- 780 24. Rotermann M. Looking back from 2020, how cannabis use and related behaviours  
781 changed in Canada. *Health Rep*. 2021;32(4):3-14. Epub 2021/04/22. doi: 10.25318/82-003-  
782 x202100400001-eng. PubMed PMID: 33881274.
- 783 25. Vaughn LK, Denning G, Stuhr KL, de Wit H, Hill MN, Hillard CJ. Endocannabinoid  
784 signalling: has it got rhythm? *British journal of pharmacology*. 2010;160(3):530-43.
- 785 26. Varni JW, Stucky BD, Thissen D, Dewitt EM, Irwin DE, Lai JS, et al. PROMIS Pediatric  
786 Pain Interference Scale: an item response theory analysis of the pediatric pain item bank. *J*  
787 *Pain*. 2010;11(11):1109-19. Epub 2010/07/16. doi: 10.1016/j.jpain.2010.02.005. PubMed PMID:  
788 20627819; PubMed Central PMCID: PMCPMC3129595.
- 789 27. Yu L, Buysse DJ, Germain A, Moul DE, Stover A, Dodds NE, et al. Development of short  
790 forms from the PROMIS™ sleep disturbance and Sleep-Related Impairment item banks. *Behav*  
791 *Sleep Med*. 2011;10(1):6-24. Epub 2012/01/19. doi: 10.1080/15402002.2012.636266. PubMed  
792 PMID: 22250775; PubMed Central PMCID: PMCPMC3261577.
- 793 28. Varni JW, Magnus B, Stucky BD, Liu Y, Quinn H, Thissen D, et al. Psychometric  
794 properties of the PROMIS® pediatric scales: precision, stability, and comparison of different  
795 scoring and administration options. *Qual Life Res*. 2014;23(4):1233-43. Epub 2013/10/03. doi:  
796 10.1007/s11136-013-0544-0. PubMed PMID: 24085345; PubMed Central PMCID:  
797 PMCPMC4312615.

- 798 29. Irwin DE, Stucky B, Langer MM, Thissen D, Dewitt EM, Lai JS, et al. An item response  
799 analysis of the pediatric PROMIS anxiety and depressive symptoms scales. *Qual Life Res.*  
800 2010;19(4):595-607. Epub 2010/03/10. doi: 10.1007/s11136-010-9619-3. PubMed PMID:  
801 20213516; PubMed Central PMCID: PMCPMC3158603.
- 802 30. Gordon JE, Powell C, Rockwood K. Goal attainment scaling as a measure of clinically  
803 important change in nursing-home patients. *Age Ageing.* 1999;28(3):275-81. Epub 1999/09/04.  
804 doi: 10.1093/ageing/28.3.275. PubMed PMID: 10475864.
- 805 31. Varni JW, Sherman SA, Burwinkle TM, Dickinson PE, Dixon P. The PedsQL Family  
806 Impact Module: preliminary reliability and validity. *Health Qual Life Outcomes.* 2004;2:55-. doi:  
807 10.1186/1477-7525-2-55. PubMed PMID: 15450120.
- 808 32. Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, et al.  
809 Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. *Neurology.*  
810 2018;90(14):e1204-e11. Epub 2018/03/16. doi: 10.1212/wnl.0000000000005254. PubMed  
811 PMID: 29540584; PubMed Central PMCID: PMCPMC5890607.
- 812 33. Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of  
813 Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. *N Engl J Med.*  
814 2018;378(20):1888-97. Epub 2018/05/17. doi: 10.1056/NEJMoa1714631. PubMed PMID:  
815 29768152.
- 816 34. Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B, Devinsky O, et  
817 al. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label  
818 extension study. *Epilepsia.* 2019;60(3):419-28. Epub 2019/02/12. doi: 10.1111/epi.14670.  
819 PubMed PMID: 30740695; PubMed Central PMCID: PMCPMC6850399.
- 820 35. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in  
821 patients with treatment-resistant epilepsy: an open-label interventional trial. *Lancet Neurol.*  
822 2016;15(3):270-8. Epub 2016/01/03. doi: 10.1016/s1474-4422(15)00379-8. PubMed PMID:  
823 26724101.
- 824 36. Raucci U, Pietrafusa N, Paolino MC, Di Nardo G, Villa MP, Pavone P, et al. Cannabidiol  
825 Treatment for Refractory Epilepsies in Pediatrics. *Front Pharmacol.* 2020;11:586110. Epub  
826 2020/10/30. doi: 10.3389/fphar.2020.586110. PubMed PMID: 33117180; PubMed Central  
827 PMCID: PMCPMC7550750.
- 828 37. Abu-Sawwa R, Scutt B, Park Y. Emerging Use of Epidiolex (Cannabidiol) in Epilepsy. *J*  
829 *Pediatr Pharmacol Ther.* 2020;25(6):485-99. Epub 2020/08/26. doi: 10.5863/1551-6776-  
830 25.6.485. PubMed PMID: 32839652; PubMed Central PMCID: PMCPMC7439947.
- 831 38. Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, et al. Long-term  
832 cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. *Epilepsia.*  
833 2019;60(2):294-302. Epub 2018/12/26. doi: 10.1111/epi.14628. PubMed PMID: 30582156;  
834 PubMed Central PMCID: PMCPMC7379690.
- 835 39. Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, et al.  
836 Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure  
837 Frequency in Dravet Syndrome: A Randomized Clinical Trial. *JAMA Neurol.* 2020;77(5):613-21.  
838 Epub 2020/03/03. doi: 10.1001/jamaneurol.2020.0073. PubMed PMID: 32119035; PubMed  
839 Central PMCID: PMCPMC7052786 compensation from Greenwich Biosciences during the  
840 conduct of the study and grants, personal fees, and other compensation from Greenwich  
841 Biosciences, nonfinancial support and other compensation from Dravet Syndrome Foundation,  
842 grants and nonfinancial support from Insys Pharmaceuticals, personal fees and nonfinancial  
843 support from BioMarin Pharmaceutical, Inc, and Upshire-Smith Laboratories, LLC, and grants,  
844 personal fees, and nonfinancial support from Zogenix, Inc, outside the submitted work. Dr  
845 Scheffer reported receiving other compensation from GW Pharmaceuticals during the conduct  
846 of the study; other from Zynerba Pharmaceuticals, Inc, Zogenix, Inc, Ovid Therapeutics, Inc,  
847 Marinus, and Ultragenyx Pharmaceutical, Inc, personal fees and other compensation from UCB,  
848 personal fees from GlaxoSmithKline, Eisai Co, Ltd, BioMarin Pharmaceutical, Inc, Nutricia, and

849 Xenon Pharmaceuticals, outside the submitted work; a patent to WO06/133508 issued; and  
850 research funding from the National Health and Medical Research Council, Health Research  
851 Council of New Zealand, and National Institutes of Health. Dr Gunning reported serving on  
852 scientific advisory boards of GW Pharmaceuticals, Zogenix, Inc, and Ovid Therapeutics,  
853 Inc/Takeda Pharmaceutical Company Limited; serving on the speaker's bureau for LivaNova  
854 plc; and serving as the principal investigator for trials sponsored by GW Research, Ltd, and  
855 Zogenix, Inc. Dr Sanchez-Carpintero reported receiving research support from GW  
856 Pharmaceuticals and Zogenix for clinical trials; serving on advisory boards for Novartis  
857 International AG, GW Pharmaceuticals, and Zogenix, Inc; and serving as a trial investigator for  
858 GW Research, Ltd and Ovid Therapeutics, Inc/Takeda Pharmaceutical Company Limited. Dr  
859 Gil-Nagel reported serving as an investigator, speaker, and advisory board member for Bial,  
860 Eisai Co, Ltd, Esteve, UCB, GW Pharmaceuticals, GW Research, Ltd, Zogenix, Inc, Stoke  
861 Therapeutics, Sanofi, and Arvelle Therapeutics. Dr Perry reported participating on advisory  
862 boards for Upsher-Smith Laboratories, LLC, and Zogenix, Inc, as a consultant for Encoded  
863 Therapeutics, Inc, and as a trial investigator for GW Research, Ltd, and Zogenix, Inc. Dr Saneto  
864 reported serving as a principal investigator on the GW Research, Ltd, trials for Dravet Syndrome  
865 Foundation and TSC; on the data safety monitoring board for a clinical study sponsored by  
866 Reata Pharmaceuticals for Friedreich ataxia; as principal investigator on a study sponsored by  
867 Stealth Pharmaceutical for primary mitochondrial myopathy; as principal investigator on a study  
868 sponsored by Zogenix, Inc, in patients with Dravet syndrome; and on the speaker's bureau for  
869 GW Pharmaceuticals. No other disclosures were reported.

870 40. Rubino T, Realini N, Braida D, Guidi S, Capurro V, Viganò D, et al. Changes in  
871 hippocampal morphology and neuroplasticity induced by adolescent THC treatment are  
872 associated with cognitive impairment in adulthood. *Hippocampus*. 2009;19(8):763-72.

873 41. Murray CH, Huang Z, Lee R, de Wit H. Adolescents are more sensitive than adults to  
874 acute behavioral and cognitive effects of THC. *Neuropsychopharmacology*. 2022;47(7):1331-8.

875 42. Almog S, Aharon-Peretz J, Vulfsons S, Ogintz M, Abalia H, Lupo T, et al. The  
876 pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients  
877 with chronic pain: A randomized, double-blinded, placebo-controlled trial. *Eur J Pain*.  
878 2020;24(8):1505-16. Epub 2020/05/24. doi: 10.1002/ejp.1605. PubMed PMID: 32445190;  
879 PubMed Central PMCID: PMC7496774 disclosures; Dr. Hayon, Mrs. Ogintz, Mrs. Abalia,  
880 and Mr. Lupo are employees of Syqe Medical; Dr. Vulfsons and Prof. Eisenberg received  
881 research support from Syqe Medical.

882 43. Silva GD, Del Guerra FB, de Oliveira Lelis M, Pinto LF. Cannabidiol in the Treatment of  
883 Epilepsy: A Focused Review of Evidence and Gaps. *Front Neurol*. 2020;11:531939. Epub  
884 2020/11/17. doi: 10.3389/fneur.2020.531939. PubMed PMID: 33192966; PubMed Central  
885 PMCID: PMC7604476.

886 44. Birnie KA, Hundert AS, Laloo C, Nguyen C, Stinson JN. Recommendations for selection  
887 of self-report pain intensity measures in children and adolescents: a systematic review and  
888 quality assessment of measurement properties. *Pain*. 2019;160(1):5-18. Epub 2018/09/05. doi:  
889 10.1097/j.pain.0000000000001377. PubMed PMID: 30180088.

890 45. Hanish AE, Lin-Dyken DC, Han JC. PROMIS Sleep Disturbance and Sleep-Related  
891 Impairment in Adolescents: Examining Psychometrics Using Self-Report and Actigraphy. *Nurs  
892 Res*. 2017;66(3):246-51. Epub 2017/04/28. doi: 10.1097/nnr.0000000000000217. PubMed  
893 PMID: 28448375; PubMed Central PMCID: PMC5426113.

894 46. Donnelly A, Fitzgerald A, Shevlin M, Dooley B. Investigating the psychometric properties  
895 of the revised child anxiety and depression scale (RCADS) in a non-clinical sample of Irish  
896 adolescents. *J Ment Health*. 2019;28(4):345-56. Epub 2018/02/16. doi:  
897 10.1080/09638237.2018.1437604. PubMed PMID: 29447056.

898 47. Forrest CB, Ravens-Sieberer U, Devine J, Becker BD, Teneralli R, Moon J, et al.  
899 Development and Evaluation of the PROMIS(®) Pediatric Positive Affect Item Bank, Child-

- 900 Report and Parent-Proxy Editions. *J Happiness Stud.* 2018;19(3):699-718. Epub 2018/05/16.  
901 doi: 10.1007/s10902-016-9843-9. PubMed PMID: 29760578; PubMed Central PMCID:  
902 PMCPMC5947961.
- 903 48. Heron KE, Everhart RS, McHale SM, Smyth JM. Using Mobile-Technology-Based  
904 Ecological Momentary Assessment (EMA) Methods With Youth: A Systematic Review and  
905 Recommendations. *J Pediatr Psychol.* 2017;42(10):1087-107. Epub 2017/05/06. doi:  
906 10.1093/jpepsy/jsx078. PubMed PMID: 28475765.
- 907 49. Krebs EE, Carey TS, Weinberger M. Accuracy of the pain numeric rating scale as a  
908 screening test in primary care. *J Gen Intern Med.* 2007;22(10):1453-8. Epub 2007/08/02. doi:  
909 10.1007/s11606-007-0321-2. PubMed PMID: 17668269; PubMed Central PMCID:  
910 PMCPMC2305860.
- 911 50. Birnie KA, McGrath PJ, Chambers CT. When does pain matter? Acknowledging the  
912 subjectivity of clinical significance. *Pain.* 2012;153(12):2311-4. Epub 2012/09/22. doi:  
913 10.1016/j.pain.2012.07.033. PubMed PMID: 22995250.
- 914 51. Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. The Patient-Reported  
915 Outcomes Measurement Information System (PROMIS) developed and tested its first wave of  
916 adult self-reported health outcome item banks: 2005-2008. *J Clin Epidemiol.* 2010;63(11):1179-  
917 94. Epub 2010/08/06. doi: 10.1016/j.jclinepi.2010.04.011. PubMed PMID: 20685078; PubMed  
918 Central PMCID: PMCPMC2965562.
- 919 52. Trottier ED, Doré-Bergeron MJ, Chauvin-Kimoff L, Baerg K, Ali S. Managing pain and  
920 distress in children undergoing brief diagnostic and therapeutic procedures. *Paediatr Child  
921 Health.* 2019;24(8):509-35. Epub 2019/12/18. doi: 10.1093/pch/pxz026. PubMed PMID:  
922 31844394; PubMed Central PMCID: PMCPMC6901171.
- 923 53. San Nicolas M, Villate A, Gallastegi M, Aizpurua-Olaizola O, Olivares M, Etxebarria N, et  
924 al. Analysis of cannabinoids in plants, marijuana products and biological tissues.  
925 *Comprehensive Analytical Chemistry.* 90: Elsevier; 2020. p. 65-102.
- 926 54. Witte JS. Genome-wide association studies and beyond. *Annu Rev Public Health.*  
927 2010;31:9-20 4 p following Epub 2010/03/20. doi: 10.1146/annurev.publhealth.012809.103723.  
928 PubMed PMID: 20235850; PubMed Central PMCID: PMCPMC3997166.
- 929 55. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation  
930 PLINK: rising to the challenge of larger and richer datasets. *Gigascience.* 2015;4:7. Epub  
931 2015/02/28. doi: 10.1186/s13742-015-0047-8. PubMed PMID: 25722852; PubMed Central  
932 PMCID: PMCPMC4342193.
- 933 56. Li Y, Willer C, Sanna S, Abecasis G. Genotype imputation. *Annu Rev Genomics Hum  
934 Genet.* 2009;10:387-406. Epub 2009/09/01. doi: 10.1146/annurev.genom.9.081307.164242.  
935 PubMed PMID: 19715440; PubMed Central PMCID: PMCPMC2925172.
- 936 57. Gibbard M, Mount D, Rassekh SR, Siden HH. Family attitudes about and experiences  
937 with medical cannabis in children with cancer or epilepsy: an exploratory qualitative study.  
938 *CMAJ Open.* 2021;9(2):E563-e9. Epub 2021/05/23. doi: 10.9778/cmajo.20200212. PubMed  
939 PMID: 34021014; PubMed Central PMCID: PMCPMC8177908.
- 940 58. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic  
941 data capture (REDCap)—a metadata-driven methodology and workflow process for providing  
942 translational research informatics support. *Journal of biomedical informatics.* 2009;42(2):377-81.
- 943 59. Grant CN, Belanger RE. Cannabis and Canada's children and youth. *Paediatr Child  
944 Health.* 2017;22(2):98-102. Epub 2018/02/27. doi: 10.1093/pch/pxx017. PubMed PMID:  
945 29480902; PubMed Central PMCID: PMCPMC5804770.
- 946 60. Öst E, Nisell M, Burgos CM, Frenckner B, Öjmyr-Joelsson M. Behavioral, emotional and  
947 social functioning in children born with congenital diaphragmatic hernia. *Pediatr Surg Int.*  
948 2018;34(6):653-61. Epub 2018/04/11. doi: 10.1007/s00383-018-4266-9. PubMed PMID:  
949 29637256; PubMed Central PMCID: PMCPMC5954068.
- 950



Monthly study visit #	1	2	3	4	5	6	7
Follow up window ( $\pm$ 5 days)							
Informed consent	X						
Medical history and demographics	X						
MPL-001 intervention follow-up		X	X	X	X	W	
Concomitant medication review	X	X	X	X	X	X	X
Physical exam	X						X
Vital signs and weight	X	X	X	X	X	X	X
Pregnancy test in females	X	X	X	X	X	X	X
Review of daily electronic headache diary	X	X	X	X	X	X	X
Sleep related impairment scale	X	X	X	X	X	X	X
Pain related interference scale	X	X	X	X	X	X	X
Family impact scale	X	X	X	X	X	X	X
Mood scales for anxiety, depression, and positive affects	X	X	X	X	X	X	X
Self-directed goal attainment	X	X	X	X	X	X	X
Participant expectation survey	X						X
Blood samples (8mLs, approx.)	X	X	X	X	X	X	X
Saliva sample for pharmacogenomics	X						
Adverse event review		X	X	X	X	X	X
Drug accountability		X	X	X	X	X	X
Visit duration (minutes)	60	45	60	45	60	45	60

Where W = weaning begins

Figure 1

# CAN-CHA Dosing Calendar

Version 2.0

Use the light grey rectangles to fill out the corresponding number of days in the month. Please mark the boxes to indicate that you have administered the CBD-enriched cannabis herbal extract oil and took your medication with food. If you lose this form please email the research coordinator to send you an electronic copy.

	SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
Morning	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>
Afternoon	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>
Morning	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>
Afternoon	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>
Morning	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>
Afternoon	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>
Morning	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>
Afternoon	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>
Morning	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>
Afternoon	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>	mL <input type="checkbox"/>
<b>NOTES</b>							
1 mL = _____ drops of CBD oil							

Participant ID: \_\_\_\_\_ Visit #: \_\_\_\_\_ Date: \_\_\_\_\_ Physician Signature: \_\_\_\_\_



Figure 2